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Background: Air pollution is known to be a leading cause of respiratory symptoms. Many cross-sectional studies
reported that air pollution caused respiratory disease in Japanese individuals in the 1960s. Japan has laws regulating air
pollution levels and providing compensation for victims of pollution-related respiratory disease. However, long-term
changes in respiratory function and symptoms in individuals who were exposed to air pollution in the 1960s have not
been well studied. This study aimed to investigate longitudinal respiratory function and symptoms in older, non-smoking,
long-term officially-acknowledged victims of pollution-related illness.
Methods: The study included 563 officially-acknowledged victims of pollution-related illness living in Kurashiki, Okayama
who were aged ≥ 65 years in 2009. Data were retrospectively collected from yearly respiratory symptom questionnaires
and spirometry examinations conducted from 2000 to 2009.
Results: Respiratory function declined significantly from 2000 to 2009 (p < 0.01), but the mean annual changes were
relatively small. The change in mean vital capacity was −40.5 ml/year in males and −32.7 ml/year in females, and the
change in mean forced expiratory volume in 1 second was −27.6 ml/year in males and −23.9 ml/year in females. Dyspnea
was the only symptom that worsened significantly from 2000 to 2009 in both sexes (males: p < 0.05, females: p < 0.01).
Conclusions: Our results suggest that the high concentrations of air pollutants around 1970 resulted in a decrease in
respiratory function and an increase in respiratory symptoms in the study population. From 2000 to 2009, the mean
annual changes in respiratory function were within the normal range, even though the severity of dyspnea worsened.
The changes in respiratory function and symptoms over the study period were probably due to aging. The laws
governing air pollution levels and providing compensation for officially-acknowledged victims of pollution-related illness
in Japan may be effective for respiratory disease cause by pollution.
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Air pollution is a serious problem throughout the world.
Epidemiological studies have reported that air pollution
is associated with adverse respiratory effects [1-7] and
increased mortality [8-10]. Some areas of Japan experi-
enced high levels of air pollution during the period of* Correspondence: tanakataka@nagasaki-u.ac.jp
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reproduction in any medium, provided the orrapid economic growth after World War II and many
people who lived in these areas complained about respira-
tory symptoms. In response, the Japanese government
implemented air pollution laws. The Basic Law for Environ-
mental Pollution Control was implemented in 1967, and air
pollution has decreased since then. The Pollution-Related
Health Damage Special Measures Law was implemented in
1969. Japanese citizens who experience health impair-
ment caused by air pollution are certified by prefectural
government committees. These officially-acknowledgedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Time required for certification of pollution-
related illness
Illness a) b) c)
Chronic bronchitis 24 months 48 months 36 months
Asthma 12 months 30 months 18 months
Emphysema 36 months 66 months 52 months
a) Individual who resided in a designated area prior to 1973.
b) Individual who did not reside in a designated area, but spent at least 8
hours per day in a designated area.
c) Individual who resided in a designated area, then relocated but continued
to work in a designated area for at least 8 hours per day.
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and compensation.
The air in Kurashiki, Okayama had a high sulfur di-
oxide (SO2) concentration in the 1960s because of the
high concentration of industrial areas. The number of
officially-acknowledged victims of pollution-related ill-
ness in Kurashiki peaked at 3,838 in 1988, which was
equivalent to 0.9% of the population of the city. An as-
sessment in 2009 revealed that this number had fallen
to 1,392. Of the 1,807 individuals (1,118 males, 689 fe-
males) who died from 1988 to 2009, the cause of death
was available for 501. These 501 individuals were 326
males (65.1%) and 175 females (34.9%) with a mean age
at death of 75.3 years (range 15–90 years); the mean
age at death was 72.3 years in males and 76.3 years in
females. The causes of death were respiratory disease
(n = 216, 43.1%), malignant neoplasm (n = 151, 30.1%),
circulatory disease (n = 77, 15.4%), and other (n = 57,
14.4%). The percentage of people aged ≥ 65 years in
Japan increased to 23% in 2009, and a similar pattern
of aging occurred in Kurashiki. Of the 1,392 victims of
pollution-related illness who were still alive in 2009, 774
(55.6%) were aged ≥ 65 years. The mean age of officially-
acknowledged victims of pollution-related illnesses in
Kurashiki is increasing, and these individuals are now
beginning to develop respiratory illnesses and complica-
tions due to aging. These combined health challenges
are of major economic and social concern [11].
Many cross-sectional studies have examined the effects
of air pollution on respiratory function based on the con-
centrations or types of pollutants. The Seattle Panel Study
[12] reported that the concentration of particulate pollut-
ants was associated with the magnitude of impairment in
respiratory function in adults. Almost all studies to date
have been cross-sectional, and few longitudinal studies
have included measurements of respiratory function. In
particular, there is a lack of studies reporting the respira-
tory symptoms and function of officially-acknowledged
victims of pollution-related illness who have received com-
pensation. Furthermore, the effects on respiratory function
and symptoms of living in a city that initially had un-
acceptably high levels of pollution, and later had lower
levels of pollution, have not been investigated.
The aim of this study was to conduct a longitudinal
assessment of respiratory symptoms and function in older
long-term officially-acknowledged victims of pollution-
related illness in Japan.
Methods
Study design and setting
This study was embedded in a longitudinal study of
officially-acknowledged victims of pollution-related ill-
ness in Kurashiki from 2000 to 2009. The study protocol
was approved by the Ethical Committee of NagasakiUniversity Graduate School of Biomedical Sciences. The
study subjects were drawn from the register of officially-
acknowledged victims of pollution-related illness in
Kurashiki. Registered victims all met the following con-
ditions as determined by the Public Relief System of
Kurashiki City, in accordance with the Pollution-Related
Health Damage Special Measures Law (1969) and the Pol
lution-Related Health Damage Compensation Law (1973):
(1) resided or spent time on activities in an area specified
as having significant air pollution (Table 1), and (2) were
diagnosed with chronic bronchitis, asthma, or emphysema
by a doctor. Registered victims were entitled to various
forms of compensation including monthly consultation
with a doctor, prescriptions for expectorants and broncho-
dilators, yearly assessment of respiratory symptoms using
a detailed questionnaire, and yearly spirometry, in accord-
ance with the Public Nuisance Countermeasures Law.
At the time that certification of pollution-related illness
ceased in 1988, the population of Kurashiki was 419,203
(204,958 males, 214,245 females), of which 3,838 were
officially-acknowledged victims of pollution-related illness
(0.9% of the total population). In 2009, the records of
these 3,838 victims were reviewed with the authorization
of the Kurashiki City Public Office (Figure 1). At that time
there were 1,392 registered survivors (634 males and 758
females). The 774 survivors (55.6%) who were aged ≥
65 years in 2009 (284 males and 490 females) were screened
for inclusion in the study. The majority of these victims
were diagnosed with chronic bronchitis (n = 528, 68.2%),
asthma (n = 242, 31.3%), or emphysema (n = 4, 0.5%) based
on their symptom as described in interviews by authorized
doctors. Chronic bronchitis was diagnosed if individuals
complained of chronic copious sputum production or per-
sistent coughing, asthma was diagnosed if they complained
of recurrent episodes of dyspnea and wheezing, and emphy-
sema was diagnosed if the symptoms did not match the cri-
teria for either bronchitis or asthma. Complete spirometry
data for the preceding 10 years were available for most vic-
tims. To avoid uneven data distribution and selection bias,
44 victims who did not have complete spirometry data for
at least 7 of the years from 2000 to 2009 were excluded. A
further 167 victims (116 males, 51 females) were excluded
≥Figure 1 Flow chart showing selection of the study subjects. The study included officially-acknowledged victims of pollution-related illness in
Kurashiki who were aged 65 years or older in 2009, and for whom the required data for statistical analysis were available.
Tanaka et al. BMC Public Health 2013, 13:766 Page 3 of 10
http://www.biomedcentral.com/1471-2458/13/766because they were former or current smokers. The re-
maining 563 victims aged ≥ 65 years were included in this
study. These victims included 156 males and 407 females
who had been certified for 25.9 ± 4.6 years (males: 26.0 ±
4.6 years, females: 25.9 ± 4.6 years). Approximately 60%
of these individuals had first been registered as
officially- acknowledged victims of pollution- related
illness in the 1970s. Date describing spirometry find-
ings and respiratory symptoms were retrospectively
collected from the yearly reviews conducted from
2000 to 2009.Air pollution monitoring
The mean daily concentrations of air pollutants were
obtained from instruments installed at 21 points in
Kurashiki. Measurement of SO2 concentration was started
in 1965, and measurement of nitrogen dioxide (NO2) con-
centration was started in 1971.Spirometry measurements
Spirometry was performed by trained staff at Mizushima-
Kyodo Hospital using an electronic spirometer (FUDAC
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formed in the sitting position, and were repeated until at
least three reproducible forced expiratory curves had been
obtained. Forced expiratory volume in 1 second (FEV1),
forced vital capacity (FVC), and vital capacity (VC) were
measured, and the FEV1/FVC (%) was calculated. Pre-
dicted FEV1 was calculated using the equation developed
by Berglund et al. [13], predicted FVC was calculated
using the equation recommended by the Special Commit-
tee of Pulmonary Physiology (Japan Respiratory Society,
1993), and predicted VC was calculated using the equation
reported by Baldwin et al. [14].
Respiratory symptoms
Respiratory symptoms (dyspnea, wheeze, cough, and spu-
tum production) were assessed by physicians during the
same season each year, using the respiratory symptoms
questionnaire provided by the government of Japan. Each
symptom was graded using a standardized 5-point scale,
as follows.
Dyspnea
1. Too breathless to leave the house, or breathless
when dressing or undressing.
2. Breathless after walking about 50 m or after a few
minutes on level ground.
3. Breathless when walking on level ground and
keeping up with people of the same age, but not
breathless when walking at own pace.
4. Breathless when walking up a slight hill or the stairs
5. Breathless only during strenuous exercise.
Wheeze
1. Severe episode ≥ 10 days each month during the
last year.
2. Severe episode ≥ 5 days each month during the last
year, or mild episode ≥ 10 days each month during
the last year.
3. Severe episode ≥ 1 day each month during the last
year, or mild episode ≥ 5 days each month during
the last year.
4. Mild episode ≥ 1 day each month during the last year.
5. No episodes of wheezing.
Cough and sputum
1. Daily cough and sputum, with a large amount of
sputum or difficulty clearing sputum.
2. Daily cough and sputum, with a moderate amount
of sputum or difficulty clearing sputum.
3. Daily cough and sputum, but not troublesome
during daily life.4. Daily cough and sputum for ≤ 3 months each year.
5. No cough or sputum.
Statistical analysis
The regression coefficients for annual mean changes in
FEV1, FEV1% predicted, FVC, VC, VC % predicted, and
FEV1/FVC (%) were calculated using simple linear re-
gression analysis. The means and standard deviations
were calculated for continuous variables, and a cross-
tabulation was constructed for categorical variables. The
Kolmogorov-Smirnov test was used to examine the distri-
bution of data. Non-normally distributed data were ana-
lyzed using nonparametric tests. Data from the time of
certification were compared between males and females
using the Mann–Whitney U test and the Kruskal-Wallis
test. Data were compared between 2000 and 2009 using
the Wilcoxon signed-rank test. Mean annual changes
in respiratory function were compared between sub-
jects with and without worsening of dyspnea using the
Mann–Whitney U test. All analyses were performed
using the PASW software package, version 18. A 2-




Figure 2 shows the annual mean daily levels of SO2 and
NO2 recorded from 1965 to 2009 in Kurashiki. The Air
Pollution Control Law was enacted in 1968. The SO2
levels were above the acceptable level for all years from
1968 to 1974, and then decreased to below 40 parts per
billion (ppb), which is the acceptable level defined by the
Air Pollution Control Law. In 1973, the acceptable NO2
level was changed by the Air Pollution Control Law from
20 ppb to 40 ppb. The NO2 level exceeded the acceptable
level only in 1973.
Patient characteristics at the time of certification
Table 2 shows the characteristics of subjects at the time
of certification. Males were significantly younger than fe-
males (p < 0.05). Males had significantly higher FEV1, FVC,
and VC than females (p < 0.001). Males had significantly
lower FEV1 % predicted (p < 0.001), FVC % predicted (p <
0.01), VC % predicted (p < 0.01), and FEV1/FVC (%) (p <
0.05) than females, but these values were all within the nor-
mal range. Many subject reported respiratory symptoms:
96.7% of males and 97.8% of females reported dyspnea
when walking on level ground and keeping up with people
of the same age (grade 1–3 symptoms on the dyspnea
scale), 93.5% of males and 96.3% of females reported at least
one episode of severe wheezing each month (grade 1–3
symptoms on the wheeze scale), and 64.1% of males and
61.9% of females reported daily cough and sputum pro-

















The Air Pollution Control Law
1968
Figure 2 Sulfur dioxide and nitrogen dioxide concentrations from 1965 to 2009 relative to standard values.
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tory symptoms were not significantly different between
the sexes.Respiratory function over time
Table 3 shows spirometry findings in 2000 and 2009 by
sex. All measurements of respiratory function declined
significantly over time (p < 0.01), except for FEV1/FVC
(%) in both sexes, FEV1 % predicted in males, and FVC %
predicted in females.
Table 4 shows comparison of the mean annual changes
in spirometry data between results in males and females
from 2000 to 2009. Only the mean annual change in VC
was significantly greater in males than in females (p < 0.05).Respiratory symptoms over time
Table 5 shows respiratory symptoms in 2000 and 2009
by sex. There was a significant worsening of dyspnea over
this time period (males: p < 0.05, females: p < 0.01). In fe-
males, there was also a significant worsening of wheeze
over this time period (p < 0.01). There was no significant
difference between 2000 and 2009 in cough and sputum
production. We examined the relationships between wors-
ening of dyspnea and mean annual changes in spirometry
measurements (Table 6). In males, the mean annual
changes in spirometry measurements were greater in those
with worsening dyspnea than those without worsening
dyspnea, but the differences were not significant. In fe-
males, however, the mean annual changes in all spirometry
measurements except FEV1/FVC (%) were significantly
greater in those with worsening dyspnea than those with-
out worsening dyspnea (all p < 0.05). For the group overall,
the mean annual changes in all spirometry measurements,
including FEV1/FVC (%), were significantly greater insubjects with worsening dyspnea than those without wors-
ening dyspnea (all p < 0.05, data not shown).
Discussion
This paper presents the first longitudinal study of respi-
ratory function and symptoms in officially-acknowledged
victims of pollution-related illness who were exposed to
air pollution at least 40 years previously, and continued to
receive various forms of compensation from the govern-
ment. Spirometry data at the time of certification, revealed
low FEV1, FEV1 % predicted, and FEV1/FVC (%). In
addition, a high proportion of victims complained of re-
spiratory symptoms. Many victims were diagnosed with
chronic bronchitis or asthma. We consider that the re-
spiratory disease in this group was caused mainly by the
high environmental levels of SO2 and NO2 during 1965 to
1974, because approximately 60% of the victims were first
registered during the 1970s. Our results are consistent
with those of past reports indicating that high environ-
mental levels of SO2 (40–60 ppb) and NO2 (17.4 ppb) can
affect the bronchi and bronchioles, resulting in respiratory
symptoms such as a cough, sputum, wheeze, and breath-
lessness [1-7,15-17]. Our results show significant differ-
ences in respiratory function between males and females
at the time of certification, with FEV1 % predicted, FVC %
predicted, VC % predicted, and FEV1/FVC (%) signifi-
cantly lower in males than in females. These differences
are thought to result from the anatomical differences be-
tween the sexes. Many studies have shown that lung vol-
umes are smaller in females than in age-matched males
[18,19]. Although, FEV1 % predicted, FVC % predicted,
VC % predicted, and FEV1/FVC (%) were significantly
lower in males than in females, respiratory symptoms
were not significantly different between males and fe-
males. This differs from previous reports that females
Table 2 Patient characteristics at the time of certification
Male (n = 156) Female (n = 407) P
Age (years) 49.6 ± 8.5 51.4 ± 8.9 <.05
Chronic bronchitis 88 (56.4%) 271 (66.6%)
0.395Asthma 66 (42.3%) 135 (33.2%)
Emphysema 2 (1.3%) 1 (0.2%)
FEV1 (l) 2.51 ± 0.75 1.93 ± 0.50 <.001
FEV1 % predicted 77 ± 21 89 ± 21 <.001
FVC (l) 3.50 ± 0.77 2.59 ± 0.52 <.001
FVC % predicted 91 ± 17 100 ± 16 <.01
VC (l) 3.67 ± 0.74 2.71 ± 0.51 <.001
VC % predicted 102 ± 18 108 ± 17 <.01
FEV1/FVC (%) 71.4 ± 14.8 74.5 ± 10.9 <.05
Dyspnea 32 (20.5%) 79 (19.4%)
0.361
91 (58.3%) 266 (65.4%)
28 (17.9%) 53 (13.0%)
3 (1.9%) 5 (1.2%)
1 (0.6%) 0 (0%)
Wheeze 47 (30.1%) 161 (39.6%)
<.05
59 (37.8%) 156 (38.3%)
40 (25.6%) 75 (18.4%)
8 (5.1%) 13 (3.2%)
1 (0.6%) 1 (0.2%)
Cough and sputum 13 (8.3%) 24 (5.9%)
0.623
87 (55.8%) 228 (56.0%)
49 (31.4%) 144 (35.4%)
6 (3.8%) 8 (2.0%)
1 (0.6%) 1 (0.2%)
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity,
VC vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation or number (%).
Male versus female: Mann–Whitney U test, Kruskal Wallis test.
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than males [20-22]. It is unknown whether sex affects the
defense mechanisms and responses to air pollution in this
study. In the current study, most of the males were work-
ing or had worked in a factory, whereas about 40% of
females were housewives during the 1960s and 1970s
[23,24]. The level of exposure therefore differed by sex,
with males exposed to more air pollution than females,
which would be expected to result in greater impairment
of lung function in males [11]. However, we could not de-
finitively determine the reasons for the differences be-
tween males and females observed in this study.
Our longitudinal analysis showed a significant decline
in respiratory function from 2000 to 2009. The mean an-
nual change in FEV1 in this study was −27.6 ml/year in
male and −23.9 ml/year in females. The mean annualchange in FEV1 reported for healthy, non-smoking males
and females aged > 65 years is −31 to −22 ml/year [25-27].
The results of the current study were within this range.
Furthermore, a previous study [28] reported that patients
with chronic obstructive pulmonary disease had a mean
annual change in FEV1 of 30–80 ml/year, which is 2 or 3
times the mean annual change in of healthy subjects,
and higher than the mean annual change of the subjects
in this study. The mean annual change in FVC in this
study was −33.4 ml/year. The mean annual change in
FVC reported for healthy, non-smoking males and females
aged > 65 years is −38 to −11 ml/year [25-27,29-31]. The
mean annual change in VC in this study was −40.6 ml/
year in males and −32.7 ml/year in females. The mean
annual change in VC reported for healthy, non-smoking
males and females aged > 65 years is −35 to –10 ml/year
[25-27,29,31,32]. The mean annual changes in FVC and
VC in this study were therefore within the previously
reported ranges for healthy, non-smoking males and fe-
males aged > 65 years. We considered that aging is the
main cause of the decline in respiratory function observed
from 2000 to 2009, with almost no additional effect cause
by exposure to air pollutions. There are several possible
reasons for the preservation of respiratory function in our
study population. The level of air pollution in Kurashiki
exceeded environmental standards until 1973, after which
it declined as a result of the establishment of environmen-
tal standards and the introduction of antipollution laws.
The NO2 level did not exceed the environmental standard
from 2000 to 2009, and continued to decrease during this
time. The SO2 level also did not exceed the environmental
standard from 2000 to 2009. Downs et al. [33] reported
that a reduction in air pollution may slow the annual rate
of decline of respiratory function in adults. Another study
showed that pollutant related delay in lung development
in children can be attenuated if the children move to
cleaner geographic areas [34]. In Switzerland, residence in
more polluted areas has been associated with reduced re-
spiratory function in adults [35]. We therefore consider
that the study population may not have had a significant
pollution- related decline in respiratory function from
2000 to 2009 because the concentrations of air pollutants
continued to decrease. Another possible explanation is that
medical treatment may have prevented deterioration of
symptoms in officially-acknowledged victims of pollution-
related illness. Reduced decline in respiratory function has
been reported following treatment with bronchodilators
such as inhaled corticosteroids, long-acting bronchial anti-
cholinergic agents, and long-acting β2 agonists [30,36-38].
It is possible that non-smoking individuals with pollution-
related illness also sought medical treatment at other
healthcare institutions, because continuous medical care is
guaranteed by the national government. However, this
study did not collect detailed data regarding treatment




Age (years) 67.0 ± 7.4 75.5 ± 7.3 <.001
FEV1 (l) 2.08 ± 0.68 1.82 ± 0.60 <.001
FEV1 % predicted 76 ± 23 75 ± 23 0.43
FVC (l) 3.01 ± 0.76 2.67 ± 0.74 <.001
FVC % predicted 90 ± 21 87 ± 22 <.01
VC (l) 3.18 ± 0.73 2.84 ± 0.72 <.001
VC % predicted 98 ± 21 92 ± 21 <.001
FEV1/FVC (%) 68.7 ± 13.7 68.4 ± 13.2 0.09
b. Female
Age (years) 68.8 ± 7.8 77.4 ± 7.8 <.001
FEV1 (l) 1.59 ± 0.44 1.39 ± 0.46 <.001
FEV1 % predicted 93 ± 28 91 ± 23 <.01
FVC (l) 2.23 ± 0.52 1.96 ± 0.56 <.001
FVC % predicted 101 ± 21 100 ± 25 0.62
VC (l) 2.31 ± 0.54 2.04 ± 0.57 <.001
VC % predicted 105 ± 21 99 ± 24 <.001
FEV1/FVC (%) 71.3 ± 10.0 71.0 ± 11.3 0.31
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, VC
vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation.
2000 versus 2009: Wilcoxon signed-rank test.
Table 5 Respiratory symptoms in 2000 and 2009
2000 2009 P
a. Male Score n = 156 n = 156
Dyspnea 1 10 (6.4%) 17 (10.9%)
<.05
2 91 (58.3%) 92 (59.0%)
3 50 (32.1%) 37 (23.7%)
4 5 (3.2%) 10 (6.4%)
5 0 (0%) 0 (0%)
Wheeze 1 40 (25.6%) 45 (28.8%)
0.84
2 60 (38.5%) 53 (34.0%)
3 45 (28.8%) 46 (29.5%)
4 11 (7.1%) 12 (7.7%)
5 0 (0%) 0 (0%)
Cough and sputum 1 0 (0%) 2 (1.3%)
0.87
2 77 (49.4%) 75 (48.1%)
3 72 (46.2%) 72 (46.2%)
4 7 (4.5%) 6 (3.8%)
5 0 (0%) 1 (0.6%)
b. Female Score n = 407 n = 406
Dyspnea 1 35 (8.6%) 41 (10.1%)
<.01
2 274 (67.3%) 282 (69.5%)
3 84 (20.6%) 73 (18.0%)
4 13 (3.2%) 10 (2.5%)
5 1 (0.2%) 0 (0%)
Wheeze 1 132 (32.4%) 156 (38.3%)
<.01
2 159 (39.1%) 137 (33.7%)
3 95 (23.3%) 97 (23.8%)
4 21 (5.1%) 17 (4.2%)
5 0 (0%) 0 (0%)
Cough and sputum 1 6 (1.5%) 13 (3.2%)
0.97
2 204 (50.1%) 201 (49.4%)
3 183 (45.0%) 182 (44.7%)
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fects of treatment on respiratory function.
Dyspnea worsened significantly in both sexes during
from 200 to 2009. The mean annual changes in respiratory
function measurements were greater in subjects with wors-
ening dyspnea than in those whose symptoms remained
unchanged. However, the mean annual changes in respira-
tory function measurements in subjects with worseningTable 4 Mean annual changes in the yearly consecutive
spirometry data in males and females from 2000 to 2009
Male Female P
FEV1 (ml) −27.6 ± 37.8 −23.9 ± 24.9 0.239
FEV1 % predicted −0.12 ± 1.48 −0.20 ± 1.66 0.221
FVC (ml) −38.0 ± 47.2 −31.8 ± 34.3 0.104
FVC % predicted −0.30 ± 1.51 −0.22 ± 1.87 0.354
VC (ml) −40.6 ± 44.2 −32.7 ± 33.9 <.05
VC % predicted −0.65 ± 1.39 −0.65 ± 1.59 0.541
FEV1/FVC (%) −0.01 ± 0.77 −0.05 ± 0.75 0.979
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, VC
vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation.
The regression coefficients for the individual mean annual changes in
pulmonary function were calculated using simple linear regression analysis.
Male versus female: Mann–Whitney U test, Kruskal-Wallis test.
4 13 (3.2%) 11 (2.7%)
5 1 (0.2%) 0 (0%)
Values are presented as number (%).
2000 versus 2009: Wilcoxon signed-rank test.dyspnea were within the range reported for healthy, non-
smoking males and females aged > 65 years. We therefore
think that these changes were due to aging. Previous stud-
ies [39,40] reported that exacerbation of dyspnea is associ-
ated with age-related decline in respiratory function in
normal elderly people. In this study, the mean annual
changes in respiratory function measurements were greater
in those with worsening dyspnea than those without wors-
ening dyspnea in females but not in males. A previous
study showed a stronger association between exposure to
air pollution and decline in respiratory function in young
Table 6 Mean annual changes in the yearly consecutive
spirometry data in subjects with and without worsening
of dyspnea
Without worsening With worsening P
a. Male n = 139 n= 17
FEV1 (ml) −25.6 ± 35.5 −43.2 ± 51.3 0.52
FEV1 % predicted −0.12 ± 1.41 −0.09 ± 2.01 0.63
FVC (ml) −35.0 ± 43.0 −58.5 ± 64.8 0.29
FVC % predicted −0.23 ± 1.41 −0.93 ± 2.02 0.32
VC (ml) −39.1 ± 43.4 −52.9 ± 49.6 0.28
VC % predicted −0.60 ± 1.37 −1.00 ± 1.60 0.51
FEV1/FVC (%) −0.04 ± 0.72 −0.24 ± 1.10 0.07
b. Female n = 367 n = 40
FEV1 (ml) −23.1 ± 25.1 −30.9 ± 22.3 <.01
FEV1 % predicted −0.27 ± 1.69 −0.40 ± 1.29 <.001
FVC (ml) −31.1 ± 35.0 −38.5 ± 26.3 <.05
FVC % predicted −0.19 ± 1.91 −0.50 ± 1.41 <.05
VC (ml) −31.4 ± 34.0 −44.6 ± 30.5 <.05
VC % predicted −0.60 ± 1.59 −1.27 ± 1.45 <.001
FEV1/FVC (%) −0.04 ± 0.73 −0.16 ± 0.90 0.13
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, VC
vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation.
Without worsening versus with worsening: Mann–Whitney U test.
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shown that females are more likely to notice a worsening
of respiratory function than males [41-44]. This may be
because males have a greater tolerance to change in re-
spiratory function [44] In addition, dyspnea which is the
subjective perception of respiratory discomfort, is a result
of complex and multifocal mechanisms [45]. These include
abnormalities in the respiratory control system, neuro-
chemical receptors, ventilation, respiratory muscles, gas
exchange, and so on [45]. Therefore, we were not able to
determine the reasons for the different relationships be-
tween worsening dyspnea and mean annual changes in
spirometry findings males and females in this study. Ap-
propriate medical treatment may have prevented the wors-
ening of wheezing (in males) and cough and sputum (in
both sexes), but the effects of medical treatment on these
symptoms could not be determined in the current study.
In our population of officially-acknowledged victims of
pollution-related illness who were living in an area
where the level of air pollutants did not exceed the en-
vironmental standards and were receiving compensation
set by the Air Pollution Control Law and the revised
Public Nuisance Countermeasures Law of Japan, treat-
ment measures were considered to be effective, and
decreases in respiratory function over time were mild.
However, dyspnea worsened significantly in both sexesfrom 2000 to 2009, and further intervention for dys-
pnea is required.
This study has some limitations. First, we evaluated only
non-smoking officially-acknowledged victims of pollution-
related illness, and did not include a control group of
subjects who lived in the same area. Second, our study
population included more females than males. This may
be partly explained by a higher death rate in males, as
65% of the deceased individuals for whom records were
available were male. The population of Kurashiki also had
a higher proportion of females than males, and more
males than females were excluded because they were
smokers. Third, spirometry testing was conducted during
various seasons. Fourth, differences in social background,
employment and lifestyle, which could have resulted in
differences in exposure to environmental pollutants, and
differences in treatment were not taken into account.
Conclusion
The results of this study suggest that the high concen-
trations of air pollutants during the 1970s affected re-
spiratory function. However, the mean annual changes
in respiratory function in officially-acknowledged victims of
pollution-related illness were within the range of healthy,
non-smoking males and females aged > 65 years, even
though the severity of dyspnea worsened over time. These
results suggest that the changes were limited to the effects
of aging. The reduction air pollution levels and the laws re-
garding pollution-related compensation and treatment in
Japan may therefore be effective for reducing respiratory
disease cause by pollution.
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